Xaliproden improves diabetic kidney disease through JNK-mediated renal tubular protection
Biochemical Pharmacology · 2026-07 · 249 · 117923
DOI: 10.1016/j.bcp.2026.117923 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-07. Verfasst von Hsin-Jou Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department and Institute of Pharmacology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Kidney Tubules. Die Arbeit nennt 55 Literaturangaben. Gefördert von: National Science and Technology Council, Taipei Veterans General Hospital.
Abstract (Originalsprache)
Diabetic kidney disease (DKD) is a major diabetic complication and the primary global cause of end-stage renal disease. Hyperglycemia triggers multiple pathological signaling pathways and ultimately leads to structural alterations and functional decline in the kidney. Xaliproden is a 5-HT1A receptor agonist originally developed for its neuroprotective effects; however, its impacts on renal disease remain unknown. The objective of this study is to investigate the therapeutic promise of xaliproden in DKD. Db/db mice were used in a mouse model of DKD in vivo, and high glucose (HG)-stimulated renal tubular epithelial cells were employed to explore the mechanistic insights in vitro. In DKD mice, xaliproden exerted reno-protective effects, as evidenced by reduced serum levels of blood urea nitrogen and creatinine as well as decreased urinary albumin-to-creatinine ratios. Furthermore, xaliproden markedly attenuated DKD-induced renal tubular injury, as indicated by decreased tubular injury score and decreased collagen deposition in kidney sections, accompanied by a reduction in inflammatory, apoptotic, and fibrotic proteins in renal tissues. In HG-stimulated renal tubular epithelial cells, xaliproden reduced the expression of inflammatory, apoptotic, and fibrotic proteins, including interleukin (IL)-1β, IL-6, tumor necrosis factor-α, cleaved caspase-3, cleaved poly-ADP-ribose polymerases, transforming growth factor β, p-Smad2/3, and collagen 1. These effects were mediated through downregulation of the c-Jun N-terminal kinase/p65/c-Jun signaling pathway. In conclusion, these findings demonstrate that xaliproden confers reno-protective effects by mitigating renal tubular epithelial cell damage and improving renal function in DKD, suggesting its potential as a therapeutic option for DKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department and Institute of Pharmacology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Division of Urology, Department of Surgery, Taipei City Hospital, Renai Branch/Zhongxing Branch/Linsen Chinese Medicine and Kunming Branch, Taipei, Taiwan; Department of Quality Management Center and Education and Resea…
- Department of Medicine, Taipei Veterans General Hospital, Yuanshan branch, Yuanshan, Yilan, Taiwan.
- Department of Medical Research and Education, Taipei Veterans General Hospital, Yuanshan branch, Yilan, Taiwan.
- Department and Institute of Pharmacology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Ph.D. Program of Interdisciplinary Medicine and Biomedical Industry, National Yang Ming Chiao Tung…
Förderung
- National Science and Technology Council
- Taipei Veterans General Hospital
Zitieren
APA
Lee, H. J., Chiang, C. H., Kuo, S. C., Chu, C. W., Lin, S. C., & Chang, T. T. (2026). Xaliproden improves diabetic kidney disease through JNK-mediated renal tubular protection. Biochemical Pharmacology, 249, 117923. https://doi.org/10.1016/j.bcp.2026.117923
Vancouver
Lee HJ, Chiang CH, Kuo SC, Chu CW, Lin SC, Chang TT. Xaliproden improves diabetic kidney disease through JNK-mediated renal tubular protection. Biochemical Pharmacology. 2026;249:117923. doi:10.1016/j.bcp.2026.117923
BibTeX
@article{Lee2026,
author = {Lee, Hsin-Jou and Chiang, Chih-Hung and Kuo, Szu-Chi and Chu, Chen-Wei and Lin, Su-Chu and Chang, Ting-Ting},
title = {Xaliproden improves diabetic kidney disease through JNK-mediated renal tubular protection},
journal = {Biochemical Pharmacology},
year = {2026},
volume = {249},
pages = {117923},
doi = {10.1016/j.bcp.2026.117923}
}
EUVIMED